Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ETCompany ParticipantsBrian Ritchie – LifeSci Advisors LLCHadar Levy ...

CrazyBulk is a performance supplement company that specializes in creating legal, over-the-counter alternatives to anabolic ...

Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask ...

With a narrative that continues to grow and become increasingly complex, Phase 5 features a variety of stories spread out ...

Phase 2A of Mumbai Metro Line 3—also called the Aqua Line—is now in its final stage. This new stretch will connect Bandra-Kurla Complex (BKC) to Acharya Atre Chowk in Worli. As per the Free Press ...

The Garmin Instinct 3 Tactical Edition has just landed It starts ... For Yours Eyes Only, you might say. A Kill Switch allows the user to perform a factory reset on the watch quickly, wiping ...

Ake­so said its PD-1xVEGF bis­pe­cif­ic an­ti­body ivonescimab beat BeiGene’s PD-1 block­er Tevim­bra in a Phase 3 study in lung can­cer pa­tients in Chi­na.

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...

Update 4/25/25 - Preorders for the Nintendo Switch 2 have come and gone. All the major retailers are currently showing "sold out." Even if you were online when preorders went live, there's a good ...

Bethesda has released two Elder Scrolls games on Nintendo Switch in the past: The Elder Scrolls V: Skyrim and The Elder Scrolls: Blades.A game like Skyrim releasing on Switch shows that it is possible ...

Gilead’s an­ti­body-drug con­ju­gate Trodelvy com­bined with Mer­ck’s Keytru­da re­duced the risk of dis­ease pro­gres­sion or death in a key study of an ag­gres­sive form of … ...